The down syndrome biomarker initiative (DSBI) pilot: Proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome

Frontiers in Behavioral Neuroscience

Volumn 9, Issue , 2015, Pages

  Rafii, Michael S ^a   Wishnek, Hannah ^a   Brewer, James B ^a   Donohue, Michael C ^b   Ness, Seth ^c   Mobley, William C ^a   Aisen, Paul S ^b   Rissman, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Down syndrome; MRI; PET; Plasma; Retinal

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; COGNITION; COGNITION ASSESSMENT; DOWN SYNDROME; FEASIBILITY STUDY; FEMALE; GENOTYPE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; IMAGING AND DISPLAY; MALE; MENTAL PERFORMANCE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RETINAL AMYLOID IMAGING; VOLUMETRY;

EID: 85074109354     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2015.00239     Document Type: Article

References (44)

1. Beacher, F., Daly, E., Simmons, A., Prasher, V., Morris, R., Robinson, C., et al. (2010). Brain anatomy and ageing in non-demented adults with down's syndrome: an in vivo MRI study. Psychol. Med. 40, 611-619. doi: 10. 1017/s0033291709990985
2. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 57, 289-300.
3. Blessed, G., Black, S. E., Butler, T., and Kay, D. W. (1991). The diagnosis of dementia in the elderly. A comparison of CAMCOG (the cognitive section of CAMDEX), the AGECAT program, DSM-III, the Mini-Mental State Examination and some short rating scales. Br. J. Psychiatry 159, 193-198. doi: 10.1192/bjp.159.2.193
4. Brewer, J. B., Magda, S., Airriess, C., and Smith, M. E. (2009). Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am. J. Neuroradiol. 30, 578-580. doi: 10. 3174/ajnr.a1402
5. Coppus, A. M., Evenhuis, H. M., Verberne, G. J., Visser, F. E., Arias-Vasquez, A., Sayed-Tabatabaei, F. A., et al. (2008). The impact of apolipoprotein E on dementia in persons with down's syndrome. Neurobiol. Aging 29, 828-835. doi: 10.1016/j.neurobiolaging.2006.12.013
6. Dalton, A. J. (1992). Dementia in down syndrome: methods of evaluation. Prog. Clin. Biol. Res. 379, 51-76.
7. Deb, S., Braganza, J., Norton, N., Williams, H., Kehoe, P. G., Williams, J., et al. (2000). APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with down's syndrome. Br. J. Psychiatry 176, 468-472. doi: 10.1192/bjp. 176.5.468
8. Donohue, M. C., Moghadam, S. H., Roe, A. D., Sun, C. K., Edland, S. D., Thomas, R. G., et al. (2014). Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers. Dement. doi: 10.1016/j.jalz.2014.07.156 [Epub ahead of print].
9. Esbensen, A. J., Rojahn, J., Aman, M. G., and Ruedrich, S. (2003). Reliability and validity of an assessment instrument for anxiety, depression and mood among individuals with mental retardation. J. Autism Dev. Disord. 33, 617-629. doi: 10. 1023/b:jadd.0000005999.27178.55
10. Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., et al. (2002). Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341-355. doi: 10.1016/S0896-6273(02)00569-X
11. Gonzalez, L. M., Anderson, V. A., Wood, S. J., Mitchell, L. A., Heinrich, L., and Harvey, A. S. (2008). The observer memory questionnaire-parent form: introducing a new measure of everyday memory for children. J. Int. Neuropsychol. Soc. 14, 337-342. doi: 10.1017/s1355617708 08020x
12. Goodenough, F. L., and Harris, D. (1950). Studies in the psychology of children's drawings. II. 1928-1949. Psychol. Bull. 47, 369-433. doi: 10.1037/h0058368
13. Handen, B. L., Cohen, A. D., Channamalappa, U., Bulova, P., Cannon, S. A., Cohen, W. I., et al. (2012). Imaging brain amyloid in nondemented young adults with down syndrome using pittsburgh compound B. Alzheimers. Dement. 8, 496-501. doi: 10.1016/j.jalz.2011.09.229
14. Hartley, S. L., Handen, B. L., Devenny, D. A., Hardison, R., Mihaila, I, Price, J. C., et al. (2014). Cognitive functioning in relation to brain amyloid-ß in healthy adults with Down syndrome. Brain 137(Pt. 9), 2556-2563. doi: 10.1093/brain/ awu173
15. Heister, D., Brewer, J. B., Magda, S., Blennow, K., McEvoy, L. K., and Alzheimer's Disease Neuroimaging, I. (2011). Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77, 1619-1628. doi: 10.1212/wnl. 0b013e3182343314
16. Hof, P. R., Bouras, C., Perl, D. P., Sparks, D. L., Mehta, N., and Morrison, J. H. (1995). Age-related distribution of neuropathologic changes in the cerebral cortex of patients with down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch. Neurol. 52, 379-391. doi: 10. 1001/archneur.1995.00540280065020
17. Hon, J., Huppert, F. A., Holland, A. J., and Watson, P. (1999). Neuropsychological assessment of older adults with down's syndrome: an epidemiological study using the Cambridge Cognitive Examination (CAMCOG). Br. J. Clin. Psychol. 38, 155-165. doi: 10.1348/014466599162719
18. Hyman, B. T., West, H. L., Rebeck, G. W., Lai, F., and Mann, D. M. (1995). Neuropathological changes in down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch. Neurol. 52, 373-378. doi: 10. 1001/archneur.1995.00540280059019
19. Jovicich, J., Czanner, S., Greve, D., Haley, E., van der Kouwe, A., Gollub, R., et al. (2006). Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 30, 436-443. doi: 10.1016/j.neuroimage.2005.09.046
20. Kovacevic, S., Rafii, M. S., Brewer, J. B., and Alzheimer's Disease Neuroimaging, I. (2009). High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis. Assoc. Disord. 23, 139-145. doi: 10.1097/wad.0b013e318192e745
21. Krasuski, J. S., Alexander, G. E., Horwitz, B., Rapoport, S. I., and Schapiro, M. B. (2002). Relation of medial temporal lobe volumes to age and memory function in nondemented adults with down's syndrome: implications for the prodromal phase of Alzheimer's disease. Am. J. Psychiatry 159, 74-81. doi: 10.1176/appi. ajp.159.1.74
22. Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., and Selkoe, D. J. (1996). Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32. doi: 10.1006/nbdi.1996. 0003
23. Luciana, M. (2003). Practitioner review: computerized assessment of neuropsychological function in children: clinical and research applications of the Cambridge Neuropsychological Testing Automated Battery (CANTAB). J. Child. Psychol. Psychiatry 44, 649-663. doi: 10.1111/1469-7610.00152
24. Moran, J. A., Rafii, M. S., Keller, S. M., Singh, B. K., Janicki, M. P., American Academy of Developmental, M., et al. (2013). The national task group on intellectual disabilities and dementia practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clin. Proc. 88, 831-840. doi: 10.1016/j.mayocp.2013.04.024
25. Mullins, D., Daly, E., Simmons, A., Beacher, F., Foy, C. M., Lovestone, S., et al. (2013). Dementia in down's syndrome: an MRI comparison with Alzheimer's disease in the general population. J. Neurodev. Disord. 5:19. doi: 10.1186/1866-1955-5-19
26. Ness, S., Rafii, M., Aisen, P., Krams, M., Silverman, W., and Manji, H. (2012). Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat. Rev. Drug Discov. 11, 655-656. doi: 10.1038/nrd3822
27. Parker, S. E., Mai, C. T., Canfield, M. A., Rickard, R., Wang, Y., Meyer, R. E., et al. (2010). Updated national birth prevalence estimates for selected birth defects in the united states, 2004-2006. Birth Defects Res. A Clin. Mol. Teratol. 88, 1008-1016. doi: 10.1002/bdra.20735
28. Pietrini, P., Dani, A., Furey, M. L., Alexander, G. E., Freo, U., Grady, C. L., et al. (1997). Low glucose metabolism during brain stimulation in older down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Am. J. Psychiatry 154, 1063-1069. doi: 10.1176/ajp.154.8.1063
29. Prasher, V. P., Sajith, S. G., Rees, S. D., Patel, A., Tewari, S., Schupf, N., et al. (2008). Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with down syndrome. Int. J. Geriatr. Psychiatry 23, 1134-1140. doi: 10.1002/gps.2039
30. Randolph, C., Tierney, M. C., Mohr, E., and Chase, T. N. (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 20, 310-319. doi: 10.1076/jcen.20.3. 310.823
31. Sabbagh, M. N., Chen, K., Rogers, J., Fleisher, A. S., Liebsack, C., Bandy, D., et al. (2015). Florbetapir PET, FDG PET and MRI in down syndrome individuals with and without Alzheimer's dementia. Alzheimers Dement. 11, 994-1004. doi: 10.1016/j.jalz.2015.01.006
32. Sabbagh, M. N., Fleisher, A., Chen, K., Rogers, J., Berk, C., Reiman, E., et al. (2011). Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with down syndrome and Alzheimer disease. Arch. Neurol. 68, 1461-1466. doi: 10.1001/archneurol.2011.535
33. Schapiro, M. B., Azari, N. P., Grady, C. L., Haxby, J. V., and Horwitz, B. (1992b). Down syndrome: differentiating mental retardation and dementia with brain imaging techniques. Prog. Clin. Biol. Res. 379, 103-122.
34. Schapiro, M. B., Haxby, J. V., and Grady, C. L. (1992a). Nature of mental retardation and dementia in down syndrome: study with PET, CT and neuropsychology. Neurobiol. Aging 13, 723-734. doi: 10.1016/0197-4580(92)90096-g
35. Schupf, N., Kapell, D., Lee, J. H., Zigman, W., Canto, B., Tycko, B., et al. (1996). Onset of dementia is associated with apolipoprotein E epsilon4 in down's syndrome. Ann. Neurol. 40, 799-801. doi: 10.1002/ana.410400518
36. Schupf, N., Patel, B., Pang, D., Zigman, W. B., Silverman, W., Mehta, P. D., et al. (2007). Elevated plasma beta-amyloid peptide Abeta(42). levels, incident dementia and mortality in down syndrome. Arch. Neurol. 64, 1007-1013. doi: 10.1001/archneur.64.7.1007
37. Schupf, N., Patel, B., Silverman, W., Zigman, W. B., Zhong, N., Tycko, B., et al. (2001). Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with down syndrome. Neurosci. Lett. 301, 199-203. doi: 10.1016/s0304-3940(01)01657-3
38. Schupf, N., Zigman, W. B., Tang, M. X., Pang, D., Mayeux, R., Mehta, P., et al. (2010). Change in plasma Ass peptides and onset of dementia in adults with down syndrome. Neurology 75, 1639-1644. doi: 10.1212/wnl. 0b013e3181fb448b
39. Sheehan, R., Sinai, A., Bass, N., Blatchford, P., Bohnen, I., Bonell, S., et al. (2015). Dementia diagnostic criteria in down syndrome. Int. J. Geriatr. Psychiatry 30, 857-863. doi: 10.1002/gps.4228
40. Sled, J. G., Zijdenbos, A. P., and Evans, A. C. (1998). A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging. 17, 87-97. doi: 10.1109/42.668698
41. Smith, P. J., Need, A. C., Cirulli, E. T., Chiba-Falek, O., and Attix, D. K. (2013). A comparison of the Cambridge Automated Neuropsychological Test Battery (CANTAB) with "traditional" neuropsychological testing instruments. J. Clin. Exp. Neuropsychol. 35, 319-328. doi: 10.1080/13803395.2013. 771618
42. Sparrow, S., and Havis, Y. (2005). Social care. Shared issues. Interview by stuart shepherd. Health Serv. J. 115, 32-33.
43. Sperling, R. A., Jack, C. R. Jr., and Aisen, P. S. (2011). Testing the right target and right drug at the right stage. Sci. Transl. Med. 3:111cm133. doi: 10. 1126/scitranslmed.3002609
44. Teipel, S. J., Alexander, G. E., Schapiro, M. B., Möller, H. J., Rapoport, S. I., and Hampel, H. (2004). Age-related cortical grey matter reductions in non-demented down's syndrome adults determined by MRI with voxel-based morphometry. Brain 127, 811-824. doi: 10.1093/brain/ awh101